Ocera Therapeutics, Inc. (OCRX)
(Delayed Data from NSDQ)
$1.79 USD
+0.02 (1.13%)
Updated Dec 8, 2017 03:59 PM ET
1.79-Market: $1.79 (%) 6:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[OCRX]
Reports for Purchase
Showing records 1 - 7 ( 7 total )
Industry: Medical - Biomedical and Genetics
Mallinckrodt to Acquire Ocera; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
It Is Not Just That Pee Is Better Than Poo: Takeaways From KOL Call; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
1Q17 Recap: We Expect a Successful End-of- Phase 2 Meeting With the FDA in 3Q; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
4Q16 Recap: Successful EOP2 Meeting in 3Q a Major Stock Catalyst; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
Subsequent Analyses of Phase 2b STOP-HE Validates OCR-002 For HE; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
STOP-HE Trial Misses While Validating Both Mechanism and Target; Maintain Buy, Drop PT to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
|